Given the potential of TLR-9 activation to trigger an anti-tumor immune response, TLR-9 agonists have been trialed as therapeutics for a wide range of malignancies, including melanoma, basal cell carcinoma, lymphoma, and renal cell carcinoma [63,64,65,66]. This evidence concerns the gene TLR9 and renal cell carcinoma.